The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Realized losses, net, on investment securities | - | 0 |
| Net loss | -3,429,124 | -6,843,054 |
| Depreciation | 75,140 | 141,690 |
| Amortization of right-of-use assets | 91,894 | 220,911 |
| Stock-based compensation | -211,279 | 327,174 |
| Shares issued in exchange for services | 99,040 | - |
| Advances, deposits, and other current assets | -155,713 | 26,277 |
| Realization of deferred income tax asset | - | 0 |
| Accounts payable and accrued liabilities | -1,222,467 | 381,116 |
| Net cash used in operating activities | -4,441,083 | -5,798,440 |
| Proceeds from sale and maturity of investment securities | - | 0 |
| Purchases of property and equipment | 0 | 276,983 |
| Purchases of investment securities | - | 0 |
| Net cash (used in) provided by investing activities | 0 | -276,983 |
| Proceeds from sale of common stock equity, net of issuance costs | 3,473,513 | 2,963,738 |
| Proceeds from issuance of common stock upon exercise of warrants | 3,467,694 | 1,967,694 |
| Issuance costs for stock dividend | 10,277 | - |
| Net cash provided by financing activities | 4,963,236 | 4,931,432 |
| Net change in cash and cash equivalents | 522,153 | -1,143,991 |
| Cash and cash equivalents at beginning of period | 5,872,767 | - |
| Cash and cash equivalents at end of period | 5,250,929 | - |
Imunon, Inc. (IMNN)
Imunon, Inc. (IMNN)